Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Breast Cancer Research : BCR|July 5, 2006
Array-CGH and breast cancerErik H van Beers, Petra M Nederlof
BMC Cancer|March 9, 2007
Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor materialSimon A Joosse, Erik H van Beers, Petra M Nederlof
Nature Communications|July 29, 2018
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effectsJoske Ubels, Pieter Sonneveld, Erik H van Beers, et al.
Experimental Hematology & Oncology|March 19, 2013
A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALCJaap Brand, Martin H van Vliet, Leonie de Best, et al.
Pharmacogenomics|January 16, 2018
Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in EuropeJennifer G Gaultney, Therese W Ng, Carin A Uyl-de Groot, et al.
The Journal of Molecular Diagnostics : JMD|November 5, 2020
Analytical Validation of SKY92 for the Identification of High-Risk Multiple MyelomaErik H van Beers, Daphne Huigh, Lizanne Bosman, et al.
Genetic Testing and Molecular Biomarkers|March 28, 2013
Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arraysMartin H van Vliet, Belinda Dumee, Erik Simons, et al.
International Journal of Laboratory Hematology|August 27, 2021
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trialsYan-Ting Chen, Erik T Valent, Erik H van Beers, et al.
Vox Sanguinis|February 11, 2026
Routine use of a spike-in DNA in-process control for foetal RHD genotyping: Testing the real-world effectiveness of this 'canary'Renske M van 't Oever, Heleen Woortmeijer, Ahmad Javadi, et al.
Vox Sanguinis|December 8, 2024
Real-world performance of a clinical droplet digital polymerase chain reaction assay for non-invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD, RhE, Rhc, RhC, K1, HPA-1a or HPA-5b: A 1-year experienceCamilla Calandrini, Onno J H M Verhagen, Ahmed Tissoudali, et al.
Pageof 2